We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Optical Virtual Biopsy Available for Urological Applications

By HospiMedica International staff writers
Posted on 05 Dec 2013
Print article
Image: The Cellvizio probe-based confocal laser endomicroscopy (pCLE) system (Photo courtesy of Mauna Kea Technologies).
Image: The Cellvizio probe-based confocal laser endomicroscopy (pCLE) system (Photo courtesy of Mauna Kea Technologies).
An optical biopsy system that allows medical staff to noninvasively assess tissues microscopically in a range of applications now includes urology.

The Cellvizio probe-based confocal laser endomicroscopy (pCLE) system generates optical biopsies, providing physicians with microscopic images of tissue instantaneously and in a minimally invasive manner. This assists them in determining whether the tissue is benign or malignant, and in making appropriate patient management decisions. Embedded real-time image processing software combined with a high-speed Laser Scanning Unit (LSU) allows the system to produce 12 frames per second (fps), so that the images stay sharp.

The system is designed in such a way that only the light-carrying components have to be inserted into the endoscope, leaving the scanning and processing outside. These optical components are assembled to form flexible confocal miniprobes, miniaturized to the point that they can be inserted into the working channel of standard endoscopes. The images thus come from a very thin focal plane that is optically projected into the tissues, an “optical slicing” capability similar in principal to the physical slicing of endoscopically extracted tissues samples in standard histology.

Probes are available for a wide range of conditions, including Barrett's Esophagus, Biliopancreatic strictures, pancreatic cysts, colorectal lesions, inflammatory bowel diseases, pulmonology and peripheral lung lesions. The new probes introduced will now provide access to flexible cystoscopy (CystoFlex), rigid cystoscopy (CystoFlex UHD), and ureteroscopy (UroFlex) procedures. The Cellvizio system is a product of Mauna Kea Technologies (Paris, France).

“Given the proven medical need and a substantial demand from the medical community for an improvement in urology procedures, we are confident in the clinical value that these new probes will provide in the treatment of bladder cancer,” said Sacha Loiseau, Founder and CEO of Mauna Kea Technologies. “The market opportunity in urology is considerable and the Cellvizio Optical Biopsy platform, which now includes the EVA operating system and a range of miniprobes specifically designed for urology applications, is ideally positioned to address it.”

“Bladder cancer has a recurrence rate of about 70%, which requires patients to be monitored throughout the rest of their lives and undergo frequent further treatments, making it the most expensive cancer to manage,” said Patrick Coloby, MD, President of the Association Française d'Urologie. “Optical biopsy would enable us to better guide and control our interventions during these procedures.”

The conventional procedure to treat urological tumors currently involves an initial endoscopic examination to detect bladder lesions (flexible cystoscopy procedure) and then resection them (rigid cystoscopy procedure), before sending analyses to a laboratory, to gauge their aggressiveness and to distinguish superficial forms and infiltrating tumors requiring surgical resection.

Related Links:

Mauna Kea Technologies


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Transvaginal Tube
LiNA McCartney Tube

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.